Study tests safer switch from street CBD to approved drug for kids with severe epilepsy
NCT ID NCT06924827
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the best way to switch children with Dravet or Lennox-Gastaut syndrome from artisanal (non-pharmaceutical) cannabidiol to Epidiolex, an FDA-approved CBD medication. About 25 children aged 2 to 18 will gradually increase their Epidiolex dose while reducing their artisanal CBD over two weeks. Researchers will track how many successfully make the switch and continue on Epidiolex for 20 weeks, monitoring side effects and seizure control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epidiolex (pharmaceutical-grade cannabidiol)
What this could lead to
If successful, this study could provide a safe, step-by-step method for switching children from unregulated CBD products to a consistent, approved medication for seizure control.
What could go wrong
This is a small, early-phase study with only 25 participants, so results may not apply to everyone. Side effects from the switch or differences in dosing could cause problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME (DS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada